Sulfation pharmacogenetics in humans

Richard M Weinshilboum, Ibrahim Aksoy

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Human tissues contain at least three well-characterized cytoplasmic sulfotransferase (ST) enzymes, thermostable (TS) and thermolabile (TL) forms of ST (PST) and dehydroepiandrosterone (DHEA) ST. Both forms of PST are expressed in an easily accessible human tissue, the blood platelet. The presence of PST in blood platelets made it possible to perform pharmacogenetic studies of these enzymes in humans. Those studied demonstrated that TS and TL PST activities in the human platelet are regulated by separate, common genetic polymorphisms. Furthermore, the platelet activity of TS, but not of TL PST is correlated with levels of this enzyme activity in other human tissues such as liver, jejunal mucosa and cerebral cortex. The pharmacogenetic strategy used to study TS and TL PST could not be applied to DHEA ST since that enzyme is not expressed in human blood elements. However, DHEA ST is expressed in the liver. When 94 samples of human hepatic biopsy tissue obtained during clinically-indicated surgery were studied, there was a 4.6-fold range of DHEA ST activity levels and a bimodal frequency distribution, with approximately 25% of the samples included in a 'high activity' subgroup. The presence of bimodality raised the possibility that human DHEA ST activity might also be regulated by a genetic polymorphism. Since a cDNA for human hepatic DHEA ST has been cloned, it will now be possible to study molecular genetic mechanisms that might be involved in the regulation of individual variation in DHEA ST activity in human hepatic tissue. Pharmacogenetic studies of ST enzymes are intended, ultimately, to determine the role of inheritance in the regulation of individual variation in the sulfate conjugation of drugs,, xenobiotics, neurotransmitters and hormones in humans.

Original languageEnglish (US)
Pages (from-to)233-246
Number of pages14
JournalChemico-Biological Interactions
Volume92
Issue number1-3
DOIs
StatePublished - 1994

Fingerprint

Pharmacogenetics
Platelets
Sulfotransferases
Tissue
Blood Platelets
Blood
Liver
Enzymes
Polymorphism
Genetic Polymorphisms
Human Activities
Biopsy
Enzyme activity
Xenobiotics
dehydroepiandrosterone sulfotransferase
Surgery
Sulfates
Neurotransmitter Agents
Complementary DNA
Cerebral Cortex

Keywords

  • Pharmacogenetics
  • Sulfate conjugation
  • Sulfation pharmacogenetics

ASJC Scopus subject areas

  • Toxicology

Cite this

Sulfation pharmacogenetics in humans. / Weinshilboum, Richard M; Aksoy, Ibrahim.

In: Chemico-Biological Interactions, Vol. 92, No. 1-3, 1994, p. 233-246.

Research output: Contribution to journalArticle

Weinshilboum, Richard M ; Aksoy, Ibrahim. / Sulfation pharmacogenetics in humans. In: Chemico-Biological Interactions. 1994 ; Vol. 92, No. 1-3. pp. 233-246.
@article{7e45a7cf57cf45fda8c91f956f3cd571,
title = "Sulfation pharmacogenetics in humans",
abstract = "Human tissues contain at least three well-characterized cytoplasmic sulfotransferase (ST) enzymes, thermostable (TS) and thermolabile (TL) forms of ST (PST) and dehydroepiandrosterone (DHEA) ST. Both forms of PST are expressed in an easily accessible human tissue, the blood platelet. The presence of PST in blood platelets made it possible to perform pharmacogenetic studies of these enzymes in humans. Those studied demonstrated that TS and TL PST activities in the human platelet are regulated by separate, common genetic polymorphisms. Furthermore, the platelet activity of TS, but not of TL PST is correlated with levels of this enzyme activity in other human tissues such as liver, jejunal mucosa and cerebral cortex. The pharmacogenetic strategy used to study TS and TL PST could not be applied to DHEA ST since that enzyme is not expressed in human blood elements. However, DHEA ST is expressed in the liver. When 94 samples of human hepatic biopsy tissue obtained during clinically-indicated surgery were studied, there was a 4.6-fold range of DHEA ST activity levels and a bimodal frequency distribution, with approximately 25{\%} of the samples included in a 'high activity' subgroup. The presence of bimodality raised the possibility that human DHEA ST activity might also be regulated by a genetic polymorphism. Since a cDNA for human hepatic DHEA ST has been cloned, it will now be possible to study molecular genetic mechanisms that might be involved in the regulation of individual variation in DHEA ST activity in human hepatic tissue. Pharmacogenetic studies of ST enzymes are intended, ultimately, to determine the role of inheritance in the regulation of individual variation in the sulfate conjugation of drugs,, xenobiotics, neurotransmitters and hormones in humans.",
keywords = "Pharmacogenetics, Sulfate conjugation, Sulfation pharmacogenetics",
author = "Weinshilboum, {Richard M} and Ibrahim Aksoy",
year = "1994",
doi = "10.1016/0009-2797(94)90066-3",
language = "English (US)",
volume = "92",
pages = "233--246",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Sulfation pharmacogenetics in humans

AU - Weinshilboum, Richard M

AU - Aksoy, Ibrahim

PY - 1994

Y1 - 1994

N2 - Human tissues contain at least three well-characterized cytoplasmic sulfotransferase (ST) enzymes, thermostable (TS) and thermolabile (TL) forms of ST (PST) and dehydroepiandrosterone (DHEA) ST. Both forms of PST are expressed in an easily accessible human tissue, the blood platelet. The presence of PST in blood platelets made it possible to perform pharmacogenetic studies of these enzymes in humans. Those studied demonstrated that TS and TL PST activities in the human platelet are regulated by separate, common genetic polymorphisms. Furthermore, the platelet activity of TS, but not of TL PST is correlated with levels of this enzyme activity in other human tissues such as liver, jejunal mucosa and cerebral cortex. The pharmacogenetic strategy used to study TS and TL PST could not be applied to DHEA ST since that enzyme is not expressed in human blood elements. However, DHEA ST is expressed in the liver. When 94 samples of human hepatic biopsy tissue obtained during clinically-indicated surgery were studied, there was a 4.6-fold range of DHEA ST activity levels and a bimodal frequency distribution, with approximately 25% of the samples included in a 'high activity' subgroup. The presence of bimodality raised the possibility that human DHEA ST activity might also be regulated by a genetic polymorphism. Since a cDNA for human hepatic DHEA ST has been cloned, it will now be possible to study molecular genetic mechanisms that might be involved in the regulation of individual variation in DHEA ST activity in human hepatic tissue. Pharmacogenetic studies of ST enzymes are intended, ultimately, to determine the role of inheritance in the regulation of individual variation in the sulfate conjugation of drugs,, xenobiotics, neurotransmitters and hormones in humans.

AB - Human tissues contain at least three well-characterized cytoplasmic sulfotransferase (ST) enzymes, thermostable (TS) and thermolabile (TL) forms of ST (PST) and dehydroepiandrosterone (DHEA) ST. Both forms of PST are expressed in an easily accessible human tissue, the blood platelet. The presence of PST in blood platelets made it possible to perform pharmacogenetic studies of these enzymes in humans. Those studied demonstrated that TS and TL PST activities in the human platelet are regulated by separate, common genetic polymorphisms. Furthermore, the platelet activity of TS, but not of TL PST is correlated with levels of this enzyme activity in other human tissues such as liver, jejunal mucosa and cerebral cortex. The pharmacogenetic strategy used to study TS and TL PST could not be applied to DHEA ST since that enzyme is not expressed in human blood elements. However, DHEA ST is expressed in the liver. When 94 samples of human hepatic biopsy tissue obtained during clinically-indicated surgery were studied, there was a 4.6-fold range of DHEA ST activity levels and a bimodal frequency distribution, with approximately 25% of the samples included in a 'high activity' subgroup. The presence of bimodality raised the possibility that human DHEA ST activity might also be regulated by a genetic polymorphism. Since a cDNA for human hepatic DHEA ST has been cloned, it will now be possible to study molecular genetic mechanisms that might be involved in the regulation of individual variation in DHEA ST activity in human hepatic tissue. Pharmacogenetic studies of ST enzymes are intended, ultimately, to determine the role of inheritance in the regulation of individual variation in the sulfate conjugation of drugs,, xenobiotics, neurotransmitters and hormones in humans.

KW - Pharmacogenetics

KW - Sulfate conjugation

KW - Sulfation pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=0028322268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028322268&partnerID=8YFLogxK

U2 - 10.1016/0009-2797(94)90066-3

DO - 10.1016/0009-2797(94)90066-3

M3 - Article

C2 - 8033256

AN - SCOPUS:0028322268

VL - 92

SP - 233

EP - 246

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 1-3

ER -